share_log

藥明合聯：截至2024年5月31日止股份發行人的證券變動月報表

WUXI XDC: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 May 2024

Hong Kong Stock Exchange ·  Jun 5 17:02
Summary by Futu AI
藥明合聯生物技術有限公司（WuXi XDC Cayman Inc.）於2024年6月5日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年5月31日的股份變動情況。報告顯示，公司的法定/註冊股本結存維持在10,000,000,000股，每股面值0.00005美元，總額500,000美元，本月無增減變動。此外，根據公司的股份期權計劃，2023年1月至10月期間授出的股份期權，本月內因行使期權所得資金總額為人民幣828,285.4元，而本月普通股增加總數為499,569股。公司確認所有證券發行均已獲得董事會批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
藥明合聯生物技術有限公司（WuXi XDC Cayman Inc.）於2024年6月5日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年5月31日的股份變動情況。報告顯示，公司的法定/註冊股本結存維持在10,000,000,000股，每股面值0.00005美元，總額500,000美元，本月無增減變動。此外，根據公司的股份期權計劃，2023年1月至10月期間授出的股份期權，本月內因行使期權所得資金總額為人民幣828,285.4元，而本月普通股增加總數為499,569股。公司確認所有證券發行均已獲得董事會批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
WuXi XDC Cayman Inc., also known as Pharmaron Biotech, submitted its latest monthly securities report to the Hong Kong Stock Exchange and Clearing Limited on June 5th, 2024, reporting on changes in shareholdings as of May 31st, 2024. The report shows that the company's statutory/registered share capital remains at 10,000,000,000 shares, with a par value of $0.00005 per share, for a total of $500,000, with no changes this month. In addition, under the company's share option plan, the total amount of funds received from exercising share options granted between January and October 2023 was RMB 828,285.4 this month, while the total number of ordinary shares increased by 499,569 shares. The company confirms that all securities issued have been approved by the board of directors and comply with the relevant requirements of the Hong Kong Stock Exchange Listing Rules.
WuXi XDC Cayman Inc., also known as Pharmaron Biotech, submitted its latest monthly securities report to the Hong Kong Stock Exchange and Clearing Limited on June 5th, 2024, reporting on changes in shareholdings as of May 31st, 2024. The report shows that the company's statutory/registered share capital remains at 10,000,000,000 shares, with a par value of $0.00005 per share, for a total of $500,000, with no changes this month. In addition, under the company's share option plan, the total amount of funds received from exercising share options granted between January and October 2023 was RMB 828,285.4 this month, while the total number of ordinary shares increased by 499,569 shares. The company confirms that all securities issued have been approved by the board of directors and comply with the relevant requirements of the Hong Kong Stock Exchange Listing Rules.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.